Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
GENEVA, SWITZERLAND / ACCESSWIRE / March 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (“Relief” or the “Company“), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that its partner, NeuroRx, Inc., has reported that work is underway to determine the feasibility of formulating RLF-100(TM) as a dry powder using TFF Pharmaceuticals’ Thin-Film Freezing (TFF) technology.
Typically, the TFF process produces high-potency powders that require minimal inactive ingredients, a benefit to drug delivery. Encapsulated TFF powders in dry powder inhalers (DPIs) exhibit aerodynamic properties that enable as much as 75% of the drug to be deposited into the deep lung. Furthermore, a drug that is converted into a powder by the TFF process can be shipped at room temperature and reconstituted at the point of administration, eliminating cold chain requirements.
Chris Stijnen, Chief Commercial Officer of Relief commented: “We are pleased with this initiative to identify an optimal, long-term stable formulation of aviptadil in a dry powder form, which could enable improved delivery of the inhaled product candidate into the lungs.”
The relevant NeuroRx press release can be found here.
###
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100(TM) (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100(TM).
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.
| CORPORATE CONTACT: RELIEF THERAPEUTICS Holding AG Chris Stijnen Chief Commercial Officer Mail: contact@relieftherapeutics.com |
MEDIA AND INVESTOR CONTACTS: MC Services AG Anne Hennecke / Brittney Sojeva Tel.: +49 (0) 211-529-252-14 Mail: relief@mc-services.eu |
View source version on accesswire.com:
https://www.accesswire.com/635434/Relief-Reports-that-NeuroRx-has-Announced-Feasibility-Collaboration-with-TFF-Pharmaceuticals
